---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-040080"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2026-08-25T21:12:15+00:00"
generated_at: "2026-08-25T21:14:09.425085+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ensysce gets Nasdaq extension on bid price; Cy deal triggers initial listing review

## Summary
- Nasdaq confirmed compliance with $2.5M stockholders' equity (Rule 5550(b)(1)) but requires evidence in next periodic report or delisting.
- Bid price cure deadline extended to Feb 22, 2027; stock had been below $1.00 for 30 consecutive days.
- Cy Biopharma acquisition deemed a Change of Control under Nasdaq Rule 5110(a); company must satisfy initial listing criteria.
- Ensysce intends to submit an initial listing application to complete the Cy transaction and convert preferred shares.
- Failure to meet listing requirements could lead to trading suspension of ENSC common stock.

## SEC filing metadata
- accession: 0001493152-26-040080
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2026-08-25T21:12:15+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315226040080/0001493152-26-040080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315226040080/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-040080
- JSON: https://secwatch.observer/filing/0001493152-26-040080.json
- Plain text: https://secwatch.observer/filing/0001493152-26-040080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.